Literature DB >> 21647844

Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence.

Bie-Yu Huang1, Chuen Hseuh, Tzu-Chieh Chao, Kun-Ju Lin, Jen-Der Lin.   

Abstract

Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are the most common differentiated thyroid cancers. Previous studies report that Hashimoto's thyroiditis (HT) concomitant with PTC is unusual and improves prognosis compared to classical PTC. Few previous studies address FTC concomitant with HT. In this study, we retrospectively analyzed data from one institution and compared clinical presentations and results of treatment of PTC and FTC with and without HT. In addition, studies comparing presentation and long term follow-up prognosis in classical PTC and FTC were conducted. A total of 1,788 PTC patients and 209 FTC patients underwent thyroidectomy with or without lymph node dissection and follow-up at Chang Gung Medical Center in Linkou, Taiwan. All thyroid carcinomas were pathologically classified according to World Health Organization criteria. Histological patterns of PTC were categorized as classical PTC, or PTC with HT. Follicular thyroid carcinoma patients were categorized as FTC or FTC with HT. The dataset contained a total of 1,703 PTC cases categorized as classical PTC, 85 cases of PTC with HT, 201 cases of FTC and eight cases of FTC with HT. Analysis of Classification of Malignant Tumors (TNM) stage revealed a higher percentage of classical PTC in stage IV than HT group (12.03% vs. 4.70%). Mean tumor size of classical PTC was larger than HT group. Although 42.3% of FTC cases presented with distant metastases, no cases of FTC with HT presented with distant metastasis. Cancer-specific mortality was higher in classical PTC group than in PTC with HT. There was 53.2% of FTC without HT assigned recurrent status, and six of them died of thyroid cancer. No cancer mortality or recurrence in HT with FTC. PTC and FTC with HT presented with better clinical stage and better prognosis after same therapeutic modality. In conclusions, both PTC and FTC with HT have less aggressive clinical presentation and better prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21647844     DOI: 10.1007/s12022-011-9164-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  25 in total

1.  Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland.

Authors:  M E DAILEY; S LINDSAY; R SKAHEN
Journal:  AMA Arch Surg       Date:  1955-02

2.  Proinflammatory mediators and genetic background in oncogene mediated tumor progression.

Authors:  John P Russell; Julie B Engiles; Jay L Rothstein
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

3.  Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study.

Authors:  Cüneyd Anil; Sibel Goksel; Alptekin Gursoy
Journal:  Thyroid       Date:  2010-06       Impact factor: 6.568

4.  The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Authors:  Tae Yong Kim; Won Bae Kim; Yoon Soo Rhee; Ja Young Song; Jung Min Kim; Gyungyub Gong; Seungkoo Lee; Sang Yoon Kim; Seong Chul Kim; Suck Joon Hong; Young Kee Shong
Journal:  Clin Endocrinol (Oxf)       Date:  2006-09       Impact factor: 3.478

5.  The association between chronic lymphocytic thyroiditis and thyroid tumors.

Authors:  Dalal M Tamimi
Journal:  Int J Surg Pathol       Date:  2002-04       Impact factor: 1.271

6.  Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.

Authors:  Suk Kyeong Kim; Kee-Ho Song; So Duk Lim; Young Chang Lim; Young Bum Yoo; Ji Soo Kim; Tae Sook Hwang
Journal:  Thyroid       Date:  2009-02       Impact factor: 6.568

7.  The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland.

Authors:  S Matsubayashi; K Kawai; Y Matsumoto; T Mukuta; T Morita; K Hirai; F Matsuzuka; K Kakudoh; K Kuma; H Tamai
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

8.  Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans.

Authors:  I Okayasu; M Fujiwara; Y Hara; Y Tanaka; N R Rose
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

9.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma.

Authors:  I Okayasu; M Saegusa; M Fujiwara; Y Hara; N R Rose
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more
  37 in total

1.  Comments on "well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence".

Authors:  Lucas Leite Cunha; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

2.  Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas.

Authors:  Lucas Leite Cunha; Laura Sterian Ward
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-16       Impact factor: 2.503

3.  Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.

Authors:  Y Liu; X Yun; M Gao; Y Yu; X Li
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

4.  Hashimoto's thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records.

Authors:  Patrizio Caturegli; Alessandra De Remigis; Kelly Chuang; Marieme Dembele; Akiko Iwama; Shintaro Iwama
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

5.  Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy.

Authors:  Marina S Carvalho; Pedro W Rosario; Gabriela F Mourão; Maria R Calsolari
Journal:  Endocrine       Date:  2016-11-23       Impact factor: 3.633

6.  Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis.

Authors:  Rong Zeng; Yi Lyu; Guoqiao Zhang; Tao Shou; Kai Wang; Heng Niu; Xinmin Yan
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

7.  Interleukins as markers of inflammation in malignant and benign thyroid disease.

Authors:  Xeni Provatopoulou; Despoina Georgiadou; Theodoros N Sergentanis; Eleni Kalogera; John Spyridakis; Antonia Gounaris; George N Zografos
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

8.  Some clinical aspects in chronic autoimmune thyroiditis associated with thyroid differentiated cancer.

Authors:  Ioana Zosin; Ioana Golu; Marioara Cornianu; Mihaela Vlad; Melania Balasa
Journal:  Maedica (Buchar)       Date:  2012-12

9.  Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study.

Authors:  Francesco Cicone; Annalisa Papa; Chiara Lauri; Anna Tofani; Camilla Virili; Marco Centanni; Francesco Scopinaro; Bruno Annibale
Journal:  Endocrine       Date:  2014-09-12       Impact factor: 3.633

10.  Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

Authors:  Donald S A McLeod; David S Cooper; Paul W Ladenson; Kenneth B Ain; James D Brierley; Henry G Fein; Bryan R Haugen; Jacqueline Jonklaas; James Magner; Douglas S Ross; Monica C Skarulis; David L Steward; Harry R Maxon; Steven I Sherman
Journal:  Thyroid       Date:  2013-09-04       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.